Action

BTK

Alt Name

Approval Jurisdiction

2017 FDA 2018 EMA

Approved for clinical use

Mantle cell lymphoma, CLL

Brutto

CAS

1420477-60-6

Commercial Vendor

AstraZeneca Acerta Pharma

Compound Image

Acalabrutinib.png

Compound name

Acalabrutinib

InChI

InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

InChI Key

WDENQIQQYWYTPO-IBGZPJMESA-N

MW

465.50

PubChem CID

71226662

Reference

Reference 2

SMILES

CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5

Approved Drug List

1